BioArctic
212
SEK
+1.05 %
BIOA B
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
7 following
+1.05%
+6.27%
+9.45%
+34.52%
-5.69%
-21.31%
+77.85%
+121.99%
+631.03%
BioArctic is a research company. The greatest business focus is found in the research and development of treatments and antibodies for diseases that affect the nervous system. Examples of various diseases mainly include Alzheimer's and Parkinson's. A large part of the research is carried out in collaboration with researchers at universities and hospitals. The company was founded in 2003 and is headquartered in Stockholm, Sweden.
Read moreMarket cap
18.74B SEK
Turnover
28.23M SEK
Revenue
616M
EBIT %
41.01 %
P/E
81.54
Dividend yield-%
-
Financial calendar
13/2
2025
Annual report '24
21/5
2025
Interim report Q1'25
28/8
2025
Interim report Q2'25
ShowingAll content types
BioArctic och Bristol Myers Squibb ingår globalt licensavtal för BioArctics pyroglutamat-amyloid-beta antikroppsprogram
BioArctic: First patient dosed in EXIST Phase 2a study in Parkinson's disease
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools